22 February 2018 | News
As per the agreement, these products will be developed and manufactured by SCD in South Korea.
Image credit- cpp.industrie.de
Global pharmaceutical company, Glenmark Pharmaceuticals has entered into an exclusive agreement with Sam Chun Dang Pharm. Co. Ltd. (SCD), to develop, manufacture and market a portfolio of ophthalmic products in the US and Canada.
As per the agreement, these products will be developed and manufactured by SCD in South Korea. Glenmark will seek all market authorizations and commercialize the products in North America.
It is expected that Glenmark will file six Abbreviated New Drug Applications (ANDAs) in the first half of 2019 for the licensed SCD ophthalmic products. According to IMS sales figures, the US brand sales for the six products was approximately $1.7 billion for calendar year 2017.